Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646093
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in ChildrenHospital Universitario de CaracasCompletedNot Applicable
NCT07646093Completed
Not Applicable
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillect...Hospital Universitario de...
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07645833
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/SNot Yet RecruitingPhase 3
NCT07645833Not Yet Recruiting
Phase 3
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/S
NCT07645820
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis FlaresCastle Biosciences IncorporatedRecruiting
NCT07645820Recruiting
—
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Fla...Castle Biosciences Incorp...
NCT07645157
Sertraline Combined With Multi-Strain Probiotics for Adolescent DepressionFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingPhase 2
NCT07645157Recruiting
Phase 2
Sertraline Combined With Multi-Strain Probiotics for Adolescent DepressionFirst Affiliated Hospital...
NCT07644442
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmedCompletedPhase 1
NCT07644442Completed
Phase 1
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male SubjectsHutchmed
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07644130
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere UniversityNot Yet RecruitingNot Applicable
NCT07644130Not Yet Recruiting
Not Applicable
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere University
NCT07644754
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory MetastasesLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07644754Not Yet Recruiting
Not Applicable
Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level...Ludwig-Maximilians - Univ...
NCT07644416
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana UniversityNot Yet RecruitingNot Applicable
NCT07644416Not Yet Recruiting
Not Applicable
Using Virtual Reality Travel to Reduce Loneliness in Older AdultsIndiana University
NCT07646431
Comparative Effects Of Clamshell And Short Arc Quadriceps Exercises In Patellofemoral PainGreen International UniversityCompletedNot Applicable
NCT07646431Completed
Not Applicable
Comparative Effects Of Clamshell And Short Arc Quadriceps Exercises In Patellofe...Green International Unive...
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07645521
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus SurgeryMansoura UniversityCompletedNot Applicable
NCT07645521Completed
Not Applicable
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation...Mansoura University
NCT07644143
Effect of A Theory-based Multicomponent eHealth Intervention ProgramTaipei Medical UniversityNot Yet RecruitingNot Applicable
NCT07644143Not Yet Recruiting
Not Applicable
Effect of A Theory-based Multicomponent eHealth Intervention ProgramTaipei Medical University
NCT07645378
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaCentre for the AIDS Programme of Research in South AfricaNot Yet RecruitingNot Applicable
NCT07645378Not Yet Recruiting
Not Applicable
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervica...Centre for the AIDS Progr...
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07644013
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First HospitalRecruiting
NCT07644013Recruiting
—
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First H...
NCT07643766
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisEnveda TherapeuticsNot Yet RecruitingPhase 2
NCT07643766Not Yet Recruiting
Phase 2
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in...Enveda Therapeutics
Result Breakdown
Not yet recruiting11 (55%)
Completed4 (20%)
Recruiting4 (20%)
Active, not recruiting1 (5%)
not_applicable9 (45%)
Phase 33 (15%)
Not Specified3 (15%)
Phase 13 (15%)
Phase 22 (10%)